ACST logo

Acasti Pharma (ACST) EBITDA

Annual EBITDA

-$11.33 M
+$6.80 M+37.50%

March 31, 2024

Summary

Performance

1-Year Change

+37.5%

3-Year Change

-15.68%

5-Year Change

+69.18%

15-Year Change

-75.66%

ACST EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.53 M

3-Year Low

-$18.12 M

Earnings dates

Last Annual Earnings Report Date

Mar 31, 2024
ACST previous annual earnings announcement was published on Mar 31, 2024

Next Annual Earnings Report Date

N/A
ACST next annual earnings announcement has not yet been scheduled

OtherACSTprofitabilitymetrics:

Annual Revenue

-
ACST annual revenue value is unknown

Annual Net Income

-$12.85 M
ACST annual net profit is -$12.85 million

Annual EBIT

-$11.37 M
ACST annual earnings before interest & taxes is -$11.37 million

Annual EPS

-$1.73
ACST annual earnings per share is -$1.73

Quarterly EBITDA

-$5.20 M
-$242.00 K-4.88%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

-45.89%

5-Year Change

+74.66%

ACST Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$17.27 M
ACST quarterly EBITDA is currently -130.13% below its historical high of $17.27 million

3-Year Low

-$5.20 M
ACST quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ACST previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

N/A
ACST next earnings announcement has not yet been scheduled

OtherACSTprofitabilitymetrics:

Quarterly Revenue

$0.00
ACST quarterly revenue is $0.00

Quarterly Net Income

-$3.43 M
ACST quarterly net profit is -$3.43 million

Quarterly EBIT

-$4.83 M
ACST quarterly earnings before interest & taxes is -$4.83 million

Quarterly EPS

-$0.30
ACST quarterly earnings per share is -$0.30

TTM EBITDA

-$16.44 M
-$3.11 M-23.37%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

-55.61%

5-Year Change

+69.1%

ACST TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$9.37 M
ACST TTM EBITDA is currently -275.45% below its historical high of $9.37 million

3-Year Low

-$18.31 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ACST previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

N/A
ACST next earnings announcement has not yet been scheduled

OtherACSTprofitabilitymetrics:

TTM Revenue

$0.00
ACST TTM revenue is $0.00

TTM Net Income

-$11.61 M
ACST TTM net profit is -$11.61 million

TTM EBIT

-$16.10 M
ACST TTM earnings before interest & taxes is -$16.10 million

TTM EPS

-$1.29
ACST TTM earnings per share is -$1.29

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$11.33 M
ACST annual EBITDA is -$11.33 million

Annual Net Income

-$12.85 M
ACST annual net profit is -$12.85 million

Annual Interest Expense

-
ACST annual interest expense value is unknown

Annual Income Tax

-$1.83 M
ACST annual income tax is -$1.83 million

Annual D&A

$11.00 K
ACST annual depreciation & amortization is $11.00 thousand

ACST EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+37.5%0.0%0.0%
3 y3 years-15.7%-45.9%-55.6%
5 y5 years+69.2%+74.7%+69.1%

ACST EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+15.7%+60.0%+149.0%at low+45.2%+11.4%
5 y5-year+15.7%+224.5%-130.1%+120.5%-275.4%+223.6%
alltimeall time+640.5%+224.5%-130.1%+294.6%-275.4%+223.6%

Acasti Pharma EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$5.20 M(+4.9%)
-$16.44 M(+23.4%)
Jun 2024
-
-$4.96 M(+53.7%)
-$13.32 M(+17.7%)
Mar 2024
-$11.33 M(-37.5%)
-$3.23 M(+6.1%)
-$11.32 M(-7.6%)
Dec 2023
-
-$3.04 M(+45.6%)
-$12.25 M(-8.8%)
Sep 2023
-
-$2.09 M(-29.4%)
-$13.43 M(-18.4%)
Jun 2023
-
-$2.96 M(-28.7%)
-$16.46 M(-8.9%)
Mar 2023
-$18.12 M(+18.1%)
-$4.16 M(-1.6%)
-$18.06 M(-1.3%)
Dec 2022
-
-$4.22 M(-17.5%)
-$18.31 M(0.0%)
Sep 2022
-
-$5.12 M(+12.2%)
-$18.31 M(+9.3%)
Jun 2022
-
-$4.56 M(+3.6%)
-$16.76 M(+9.2%)
Mar 2022
-$15.34 M(+56.7%)
-$4.40 M(+4.2%)
-$15.34 M(+19.6%)
Dec 2021
-
-$4.22 M(+18.4%)
-$12.82 M(+21.4%)
Sep 2021
-
-$3.57 M(+13.4%)
-$10.56 M(+12.8%)
Jun 2021
-
-$3.15 M(+66.8%)
-$9.36 M(-4.4%)
Mar 2021
-$9.79 M(-57.3%)
-$1.89 M(-4.0%)
-$9.79 M(-204.5%)
Dec 2020
-
-$1.96 M(-17.1%)
$9.37 M(-6651.0%)
Sep 2020
-
-$2.37 M(-33.7%)
-$143.00 K(-99.2%)
Jun 2020
-
-$3.57 M(-120.7%)
-$18.31 M(-20.2%)
Mar 2020
-$22.95 M(-37.6%)
$17.27 M(-250.5%)
-$22.95 M(-56.9%)
Dec 2019
-
-$11.47 M(-44.1%)
-$53.19 M(+19.5%)
Sep 2019
-
-$20.53 M(+150.1%)
-$44.50 M(+8.7%)
Jun 2019
-
-$8.21 M(-36.7%)
-$40.96 M(+8.3%)
Mar 2019
-$36.76 M(+157.0%)
-$12.98 M(+365.7%)
-$37.80 M(+24.7%)
Dec 2018
-
-$2.79 M(-83.6%)
-$30.31 M(-4.5%)
Sep 2018
-
-$16.99 M(+236.2%)
-$31.75 M(+78.5%)
Jun 2018
-
-$5.05 M(-7.9%)
-$17.79 M(+24.5%)
Mar 2018
-$14.30 M(+121.8%)
-$5.49 M(+29.8%)
-$14.29 M(+62.3%)
Dec 2017
-
-$4.23 M(+39.9%)
-$8.80 M(+49.3%)
Sep 2017
-
-$3.02 M(+94.5%)
-$5.90 M(+40.9%)
Jun 2017
-
-$1.55 M(+17.5%)
-$4.18 M(-22.1%)
Mar 2017
-$6.45 M
-
-
DateAnnualQuarterlyTTM
Nov 2016
-
-$1.32 M(+1.0%)
-$5.37 M(+2.5%)
Aug 2016
-
-$1.31 M(-27.3%)
-$5.24 M(+18.6%)
May 2016
-
-$1.80 M(+91.4%)
-$4.42 M(+51.3%)
Feb 2016
-$2.89 M(-64.0%)
-$941.50 K(-20.8%)
-$2.92 M(-75.9%)
Nov 2015
-
-$1.19 M(+144.0%)
-$12.12 M(+55.5%)
Aug 2015
-
-$487.10 K(+60.6%)
-$7.80 M(-23.4%)
May 2015
-
-$303.30 K(-97.0%)
-$10.18 M(+25.8%)
Feb 2015
-$8.04 M(-9.1%)
-$10.14 M(-423.1%)
-$8.09 M(>+9900.0%)
Nov 2014
-
$3.14 M(-209.2%)
-$37.70 K(-99.3%)
Aug 2014
-
-$2.87 M(-260.8%)
-$5.66 M(+5.2%)
May 2014
-
$1.79 M(-185.5%)
-$5.38 M(-39.6%)
Feb 2014
-$8.84 M(+45.4%)
-$2.09 M(-15.7%)
-$8.91 M(+5.7%)
Nov 2013
-
-$2.48 M(-4.4%)
-$8.43 M(+13.9%)
Aug 2013
-
-$2.59 M(+48.7%)
-$7.40 M(+15.6%)
May 2013
-
-$1.74 M(+8.2%)
-$6.41 M(+6.3%)
Feb 2013
-$6.08 M(+3.8%)
-$1.61 M(+10.9%)
-$6.03 M(+1.0%)
Nov 2012
-
-$1.45 M(-9.0%)
-$5.97 M(-8.0%)
Aug 2012
-
-$1.60 M(+16.8%)
-$6.49 M(+0.2%)
May 2012
-
-$1.37 M(-11.8%)
-$6.48 M(+8.2%)
Feb 2012
-$5.86 M(+145.2%)
-$1.55 M(-21.5%)
-$5.99 M(+12.0%)
Nov 2011
-
-$1.97 M(+24.5%)
-$5.35 M(+34.8%)
Aug 2011
-
-$1.59 M(+81.1%)
-$3.97 M(+38.3%)
May 2011
-
-$876.20 K(-3.8%)
-$2.87 M(+22.4%)
Feb 2011
-$2.39 M(+56.2%)
-$910.40 K(+52.9%)
-$2.34 M(+26.7%)
Nov 2010
-
-$595.60 K(+22.3%)
-$1.85 M(+13.4%)
Aug 2010
-
-$486.90 K(+38.8%)
-$1.63 M(+2.3%)
May 2010
-
-$350.70 K(-15.7%)
-$1.59 M(+5.8%)
Feb 2010
-$1.53 M
-$415.90 K(+10.3%)
-$1.51 M(+38.2%)
Nov 2009
-
-$376.90 K(-16.2%)
-$1.09 M(+21.0%)
Aug 2009
-
-$449.80 K(+71.0%)
-$900.90 K(+99.7%)
May 2009
-
-$263.00 K(+39.8%)
-$451.10 K(+139.8%)
Nov 2008
-
-$188.10 K
-$188.10 K

FAQ

  • What is Acasti Pharma annual EBITDA?
  • What is the all time high annual EBITDA for Acasti Pharma?
  • What is Acasti Pharma annual EBITDA year-on-year change?
  • What is Acasti Pharma quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Acasti Pharma?
  • What is Acasti Pharma quarterly EBITDA year-on-year change?
  • What is Acasti Pharma TTM EBITDA?
  • What is the all time high TTM EBITDA for Acasti Pharma?
  • What is Acasti Pharma TTM EBITDA year-on-year change?

What is Acasti Pharma annual EBITDA?

The current annual EBITDA of ACST is -$11.33 M

What is the all time high annual EBITDA for Acasti Pharma?

Acasti Pharma all-time high annual EBITDA is -$1.53 M

What is Acasti Pharma annual EBITDA year-on-year change?

Over the past year, ACST annual EBITDA has changed by +$6.80 M (+37.50%)

What is Acasti Pharma quarterly EBITDA?

The current quarterly EBITDA of ACST is -$5.20 M

What is the all time high quarterly EBITDA for Acasti Pharma?

Acasti Pharma all-time high quarterly EBITDA is $17.27 M

What is Acasti Pharma quarterly EBITDA year-on-year change?

Over the past year, ACST quarterly EBITDA has changed by $0.00 (0.00%)

What is Acasti Pharma TTM EBITDA?

The current TTM EBITDA of ACST is -$16.44 M

What is the all time high TTM EBITDA for Acasti Pharma?

Acasti Pharma all-time high TTM EBITDA is $9.37 M

What is Acasti Pharma TTM EBITDA year-on-year change?

Over the past year, ACST TTM EBITDA has changed by $0.00 (0.00%)